Mitchell & Pahl Private Wealth LLC Raises Stock Position in Novartis AG (NYSE:NVS)

Mitchell & Pahl Private Wealth LLC grew its holdings in Novartis AG (NYSE:NVS) by 5.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,184 shares of the company’s stock after acquiring an additional 1,219 shares during the period. Mitchell & Pahl Private Wealth LLC’s holdings in Novartis were worth $2,159,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in NVS. Ballentine Partners LLC boosted its stake in Novartis by 4.5% during the fourth quarter. Ballentine Partners LLC now owns 19,234 shares of the company’s stock valued at $1,872,000 after buying an additional 824 shares during the last quarter. Koshinski Asset Management Inc. boosted its position in shares of Novartis by 6.5% during the 4th quarter. Koshinski Asset Management Inc. now owns 2,137 shares of the company’s stock valued at $208,000 after acquiring an additional 131 shares during the last quarter. FLC Capital Advisors grew its holdings in shares of Novartis by 9.3% in the fourth quarter. FLC Capital Advisors now owns 2,586 shares of the company’s stock valued at $252,000 after purchasing an additional 220 shares in the last quarter. Diversify Wealth Management LLC increased its position in Novartis by 17.4% in the fourth quarter. Diversify Wealth Management LLC now owns 7,240 shares of the company’s stock worth $717,000 after purchasing an additional 1,072 shares during the last quarter. Finally, Smart Money Group LLC raised its stake in Novartis by 7.1% during the fourth quarter. Smart Money Group LLC now owns 9,144 shares of the company’s stock valued at $890,000 after purchasing an additional 606 shares in the last quarter. Institutional investors own 13.12% of the company’s stock.

Novartis Trading Down 0.4 %

Shares of NYSE NVS opened at $97.51 on Tuesday. Novartis AG has a twelve month low of $92.35 and a twelve month high of $120.92. The firm has a market cap of $199.30 billion, a PE ratio of 11.32, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. The business has a fifty day simple moving average of $100.61 and a two-hundred day simple moving average of $109.01. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. Novartis had a return on equity of 34.80% and a net margin of 35.96%. The firm had revenue of $12.82 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same period in the previous year, the company posted $1.74 earnings per share. Analysts expect that Novartis AG will post 7.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. BMO Capital Markets upped their price objective on Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research report on Wednesday, October 30th. HSBC downgraded Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Finally, Erste Group Bank reissued a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Two analysts have rated the stock with a sell rating and seven have issued a hold rating to the company. According to MarketBeat, Novartis currently has a consensus rating of “Hold” and an average target price of $121.50.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.